

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Melodiol Global Health Limited
<b>ABN</b>	89 609 406 911

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Bruce Linton
<b>Date of last notice</b>	3 February 2023

#### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	HSBC Custody Nominees (Australia) Limited and Canaccord Genuity Corp <Bruce Linton A/C> are nominee entities for director, Bruce Linton.
<b>Date of change</b>	27 October 2023
<b>No. of securities held prior to change</b>	<p><u>Direct:</u></p> <p>5,411,884 Fully Paid Ordinary Shares 30,000,000 ME1OPT33 Options(\$0.039, 23/12/2025)</p> <p><u>Indirect:</u></p> <p>HSBC Custody Nominees (Australia) Limited</p> <p>5,000,000 Fully Paid Ordinary Shares 5,000,000 ME1OD Options (\$0.08, 31/01/2027)</p> <p>Canaccord Genuity Corp &lt;Bruce Linton A/C&gt;</p> <p>10,000,000 ME1OPT46 Options (\$0.09, 17/01/2024)</p>

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>Class</b>	Fully Paid Ordinary Shares
<b>Number acquired</b>	2,732,213 Fully Paid Ordinary Shares
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Deemed issue price of \$0.0122 per Share. Issue of shares in lieu of \$33,333 worth of directors fees payable to Mr Linton.  Refer to Resolution 11 of the Notice of Meeting dated 12 September 2023 for further information.
<b>No. of securities held after change</b>	<u>Direct:</u>  8,144,097 Fully Paid Ordinary Shares 30,000,000 ME1OPT33 Options (\$0.039, 23/12/2025)  <u>Indirect:</u>  <i>HSBC Custody Nominees (Australia) Limited</i>  5,000,000 Fully Paid Ordinary Shares 5,000,000 ME1OD Options (\$0.08, 31/01/2027)  <i>Canaccord Genuity Corp &lt;Bruce Linton A/C&gt;</i>  10,000,000 ME1OPT46 Options (\$0.09, 17/01/2024)
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of shares in lieu of \$33,333 worth of directors fees payable to Mr Linton.  Refer to Resolution 11 of the Notice of Meeting dated 12 September 2023 for further information.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Melodiol Global Health Limited
<b>ABN</b>	89 609 406 911

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Jodi Scott
<b>Date of last notice</b>	14 October 2022

#### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
<b>Date of change</b>	27 October 2023
<b>No. of securities held prior to change</b>	209,364,678 Fully Paid Ordinary Shares
<b>Class</b>	Fully Paid Ordinary Shares
<b>Number acquired</b>	11,405,312 Fully Paid Ordinary Shares
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Deemed issue price of \$0.008 per Share. Issue of shares in conversion of one quarter of Ms Scott's salary (A\$91,242.50).  Refer to Resolution 32 of the Notice of Meeting dated 12 September 2023 for further information.
<b>No. of securities held after change</b>	220,769,990 Fully Paid Ordinary Shares

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<p><b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Issue of shares in conversion of one quarter of Ms Scott's salary (A\$91,242.50).</p> <p>Refer to Resolution 32 of the Notice of Meeting dated 12 September 2023 for further information.</p>
---	--

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Melodiol Global Health Limited
<b>ABN</b>	89 609 406 911

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Micheline MacKay
<b>Date of last notice</b>	24 January 2022

#### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
<b>Date of change</b>	27 October 2023
<b>No. of securities held prior to change</b>	Nil.
<b>Class</b>	Fully Paid Ordinary Shares
<b>Number acquired</b>	3,119,667 Fully Paid Ordinary Shares
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Deemed issue price of \$0.009 per Share. Issue of shares as part of Micheline MacKay's remuneration package.  Refer to Resolution 25 of the Notice of Meeting dated 12 September 2023 for further information.
<b>No. of securities held after change</b>	3,119,667 Fully Paid Ordinary Shares

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of shares as part of Micheline MacKay's remuneration package.  Refer to Resolution 25 of the Notice of Meeting dated 12 September 2023 for further information.
---	---

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Melodiol Global Health Limited
<b>ABN</b>	89 609 406 911

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	William Lay
<b>Date of last notice</b>	26 October 2023

#### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Noble House Consulting Ltd - a director-related entity.
<b>Date of change</b>	27 October 2023 & 2 November 2023
<b>No. of securities held prior to change</b>	12,500,000 Fully Paid Ordinary Shares 1,666,667 ME1O Options (\$0.25, 2/11/2024) 10,000,000 ME1OPT41 Options (\$0.18, 6/09/2024) 10,000,000 ME1OPT42 Options (\$0.25, 6/09/2024) 2,500,000 ME1OD Options (\$0.08, 31/01/2027) 10,000,000 ME1OPT56 Options (\$0.20, 17/01/2024) 5,000,000 ME1PERR43 Performance Rights – vested and exercisable into Shares at election 7,500,000 ME1PERR51 Performance Rights
<b>Class</b>	<ul style="list-style-type: none"> <li>• Fully Paid Ordinary Shares</li> <li>• ME1PERR52 Performance Rights</li> <li>• ME1PERR43 Performance Rights</li> </ul>
<b>Number acquired</b>	<ul style="list-style-type: none"> <li>• 25,000,000 Fully Paid Ordinary Shares</li> <li>• 5,000,000 Fully Paid Ordinary Shares</li> <li>• 50,000,000 ME1PERR52 Performance Rights</li> </ul>

+ See chapter 19 for defined terms.



## Appendix 3Y Change of Director's Interest Notice

<b>Number disposed</b>	<ul style="list-style-type: none"> <li>5,000,000 ME1PERR43 Performance Rights</li> </ul>
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<p>Nil cash consideration.</p> <p>Issue of 25,000,000 shares and 50,000,000 performance rights in consideration for Mr Lay's services as CEO and Managing Director, and to provide a performance linked incentive component in the remuneration package of Mr Lay. Refer to Resolution 30 of the Notice of Meeting dated 12 September 2023 for further information.</p> <p>Issue of 5,000,000 shares upon conversion of 5,000,000 ME1PERR43 Performance Rights.</p>
<b>No. of securities held after change</b>	<p>42,500,000 Fully Paid Ordinary Shares</p> <p>1,666,667 ME1O Options (\$0.25, 2/11/2024)</p> <p>10,000,000 ME1OPT41 Options (\$0.18, 6/09/2024)</p> <p>10,000,000 ME1OPT42 Options (\$0.25, 6/09/2024)</p> <p>2,500,000 ME1OD Options (\$0.08, 31/01/2027)</p> <p>10,000,000 ME1OPT56 Options (\$0.20, 17/01/2024)</p> <p>7,500,000 ME1PERR51 Performance Rights</p> <p>50,000,000 ME1PERR52 Performance Rights</p>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	<p>Issue of 25,000,000 shares and 50,000,000 performance rights in consideration for Mr Lay's services as CEO and Managing Director, and to provide a performance linked incentive component in the remuneration package of Mr Lay. Refer to Resolution 30 of the Notice of Meeting dated 12 September 2023 for further information.</p> <p>Issue of 5,000,000 shares upon conversion of 5,000,000 ME1PERR43 Performance Rights.</p>

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.